Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04559568 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3522348 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT04559568 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 65 participants.
The verdict
NCT04559568, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
The main purpose of this study in healthy participants is to learn more about the safety of LY3522348 and any side effects that might be associated with it. Blood tests will be performed to check how much LY3522348 gets into the bloodstream and how long it takes the body to eliminate it. This study has two parts: Part A will last up to about six weeks and Part B will last up to about eight weeks for each participant.
Interventions
- DRUG Placebo
- DRUG Midazolam
- DRUG LY3522348
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2020-10-15 |
| Est. Completion | 2021-08-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04559568
The ClinicalTrials.gov registry entry for NCT04559568 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04559568 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04559568 about?
NCT04559568 is a clinical study titled "A Study of LY3522348 in Healthy Participants". The main purpose of this study in healthy participants is to learn more about the safety of LY3522348 and any side effects that might be associated with it. Blood tests will be performed to check how much LY3522348 gets into the bloodstream and how long it takes the body to eliminate it. This study ...
What is the current status of trial NCT04559568?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2020-10-15. Estimated completion is 2021-08-17.
What interventions are being tested in trial NCT04559568?
The interventions under investigation include: Placebo (DRUG), Midazolam (DRUG), LY3522348 (DRUG).
Who is sponsoring clinical trial NCT04559568?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.